This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q66045530
rdf:type
wikibase:Item
schema:description
клінічне випробування klinisch onderzoek clinical trial կլինիկական փորձարկում ensayu clínicu
rdfs:label
A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD
skos:prefLabel
A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD
schema:name
A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD
p:P1476
wds:Q66045530-EAD51AFE-83D6-49A5-BC76-388D1839080E
wdt:P1476
A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of Adult Growth Hormone Deficiency (AGHD)
p:P582
wds:Q66045530-D1FEC818-C23F-49A3-AC00-A6D4A9DE0F9B
wdt:P582
2022-02-01T00:00:00Z
p:P31
wds:Q66045530-8C93F1FD-A8EA-4994-B747-ECBAD43893BE
wdt:P31
wd:Q30612
p:P580
wds:Q66045530-62504118-6B4E-424D-95A4-55D878C13000
wdt:P580
2017-04-01T00:00:00Z
p:P6153
wds:Q66045530-5A271210-D567-49A8-91C9-0D4B6F99ADAF wds:Q66045530-FBB351AD-F547-4709-9D62-381E335AD7C6 wds:Q66045530-DA9D192A-DF9E-4C44-87EE-372670029565 wds:Q66045530-E3E8EC98-31EE-4166-8BCD-AAB41A6ABFF2
wdt:P6153
wd:Q10924832 wd:Q30269706 wd:Q16955 wd:Q5695499
p:P2899
wds:Q66045530-B5BC2E4E-8947-4CD3-AC9E-10A18D587AF2
wdt:P2899
18
p:P1132
wds:Q66045530-FB5A7B82-27E9-46B4-AA27-8C9226F575B8
wdt:P1132
180
p:P767
wds:Q66045530-23E527BF-4051-4D4F-BCD1-D1751C9E380B
wdt:P767
wd:Q30296170
p:P4135
wds:Q66045530-9A5481AD-24C1-4F08-B109-310A93D3B6B1
wdt:P4135
60
p:P8363
wds:Q66045530-3120B6F7-1ED0-40A4-A305-9441A499BF3A
wdt:P8363
wd:Q78089383
p:P3098
wds:Q66045530-18F17D06-DF79-4A79-9BE3-25A6E0B3509F
wdt:P3098
NCT03104010
p:P6099
wds:Q66045530-A9289588-BB5C-4481-BA79-6EEF35017275
wdt:P6099
wd:Q42824440